Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
Study sponsor: Scynexis, Inc. · SCYX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-16Actual
Enrollment · participants150Actual
Source updated2024-07-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.